For decades, the gold standard in oncology has been based on population averages. We treated "cancer types" rather than "individual biology." As of January 8, 2026, the data suggests that era is ending.
The I-PREDICT trial results, published yesterday in the Journal of Clinical Oncology (JCO), have provided the definitive clinical proof-of-concept for N-of-1 personalized combination therapy.
The Breakthrough Evidence
In a cohort of 210 patients with advanced, refractory cancers, researchers uncovered a level of biological complexity that traditional protocols simply cannot address:
- Individualized Complexity: 95% of patients had a completely unique tumour DNA profile. No two cancers were alike.
- Tailored Regimens: This required the administration of 157 different treatment regimens, including 103 novel drug pairings that had never been tested together before.
- Safety & Success: By utilizing individualized dose ascertainment (starting with reduced doses and titrating up based on tolerance), these novel combinations were delivered safely, leading to significantly higher response rates and longer survival.
The Value for Modern Practice
This study shifts the conversation from what drug we use to how we design the strategy. Precision is no longer just about finding a single "driver mutation"; it is about addressing the entire molecular portfolio of the tumor simultaneously.
For the modern oncologist, the "Molecular Tumor Board" is becoming as essential as the stethoscope. We are moving toward a future where treatment is as unique as the patient’s own DNA.
Reference: - Sicklick, J. K., Kato, S., et al. (2026). Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations. Journal of Clinical Oncology. DOI: 10.1200/JCO-25-01453.